{4-[1-(5-chloro-2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazin-7-yl]-phenyl}-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone | 957194-90-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[1-(5-chloro-2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazin-7-yl]-phenyl}-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone
• 英文别名: [4-[1-[[5-chloro-2-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2H-pyrido[2,3-b]pyrazin-7-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone
• CAS: 957194-90-0
• 化学式: C₃₁H₃₃ClF₃N₅O
• 分子量: 584.084
• InChiKey: JVVGHVJDZJSKRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  41
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  51.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1-(5-chloro-2-trifluoromethyl-benzyl)-7-iodo-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine 、 [4-(pyrrolidin-1-yl)piperidin-1-yl][4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanone 以to give the title compound as an orange foam (19% yield)的产率得到{4-[1-(5-chloro-2-trifluoromethyl-benzyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazin-7-yl]-phenyl}-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone
  参考文献：
  名称：

  Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors

  摘要：

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。

  公开号：

  US07919502B2

文献信息

• Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
  申请人：Dorsey D. Bruce

  公开号：US20080032972A1

  公开（公告）日：2008-02-07

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了化合物I的结构或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。化合物I具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病症。
• PYRIDOPYRAZINES AND DERIVATIVES THEREOF AS ALK AND c-MET INHIBITORS
  申请人：Dorsey Bruce D.

  公开号：US20100048576A1

  公开（公告）日：2010-02-25

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了I式化合物或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。I式化合物具有ALK和/或c-Met抑制活性，可用于治疗ALK或c-Met介导的疾病或病状。
• Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
  申请人：Cephalon, Inc.

  公开号：US08080561B2

  公开（公告）日：2011-12-20

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors
  申请人：Cephalon, Inc.

  公开号：US07919502B2

  公开（公告）日：2011-04-05

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS
  申请人：CEPHALON, INC.

  公开号：EP2091951B1

  公开（公告）日：2018-02-28